CYP2C19*17 gene polymorphism–A pilot study
DOI:
https://doi.org/10.48047/Keywords:
CYP2C19*17, genotype ultra-rapid metabolizers, IHD (Ischemic heart disease)Abstract
Background: Cytochrome P450 2C19 (CYP2C19) play a versatile role in the metabolism of drugs.
CYP2C19*17 variant allele increases the metabolic activity of the CYP2C19 resulting in ultra-rapid
metabolizers phenotype in the individuals and decreases the therapeutic levels of substrate. Studies
show that there are inter-ethnic differences in allele distribution.
Methods: We recruited 48 IHD patients, demographic and biochemical parameters collected and
genotype for CYP2C19*17 were studied using nested PCR-restriction fragment length polymorphism
(PCR-RFLP) method. Statistical analyses were carried out using SPSS software.
Results: The total allelic frequency of CYP2C19*17 was found to be 20% in our study population.
Among the study subjects, 4.2% were homozygous mutant, 33.3% heterozygous and 62.5%
homozygous wild genotype.
Conclusion: The frequency of CYP2C19*17 is less compared to other studies. This may be due to the
small sample size and inter-ethnic differences. So further elaborate study is essential to evaluate the
genotype-phenotype association and clinical utility of this variant.
